Never saw ZACKS INVESTMENT to cover OTC - pink Market penny stock .... but Surprise ...
Zacks Investment Research Upgrades Innovus Pharmaceuticals Inc (INNV) to Buy
August 17th, 2016
Innovus Pharmaceuticals logoInnovus Pharmaceuticals Inc (NASDAQ:INNV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $0.50 target price on the stock. Zacks Investment Research’s target price suggests a potential upside of 27.88% from the company’s current price.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Innovus Pharmaceuticals (NASDAQ:INNV) traded down 5.115% on Wednesday, hitting $0.371. The company had a trading volume of 1,042,997 shares. The stock’s 50-day moving average price is $0.38 and its 200 day moving average price is $0.18. The company’s market capitalization is $32.34 million. Innovus Pharmaceuticals has a one year low of $0.03 and a one year high of $0.66.
AI
